8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 31, 2017

Nuo Therapeutics, Inc.

(Exact name of Registrant as Specified in Charter)

Delaware	001-32518	23-3011702
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

207A Perry Parkway, Suite 1, Gaithersburg, MD 20877

(Address of Principal Executive Offices) (Zip Code)

(240) 499-2680

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Item 7.01. Regulation FD Disclosure.

As previously reported by Nuo Therapeutics, Inc. (the “Company”), on January 26, 2016, the Company filed a voluntary petition in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) seeking relief under Chapter 11 of Title 11 of the United States Code, which is being administered under the caption “In re: Nuo Therapeutics, Inc.”, Case No. 16-10192 (MFW). On May 5, 2016, the Company's Modified First Amended Plan of Reorganization went effective.

On January 31, 2017, the Company filed its unaudited Quarterly Operating Report for the period between October 1, 2016 and December 31, 2016 (the “Quarterly Operating Report”) with the Bankruptcy Court.   It is important for investors and potential investors to note that the financial statements in the Quarterly Operating Report were not audited, were not prepared in accordance with accounting principles generally accepted in the United States and are in a format prescribed by applicable bankruptcy laws and regulations.   The Quarterly Operating Report is limited in scope and only covers a limited time period.  The Company cautions investors and potential investors not to place undue reliance on the information contained in the Quarterly Operating Report, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company.  Instead, the Quarterly Operating Report was prepared solely for the purpose of complying with the reporting requirements of the Office of the United States Trustee, and is furnished as an Exhibit to this Form 8-K solely for purposes of Regulation FD.  

There can be no assurance that, from the perspective of an investor or potential investor in the Company’s securities, the Quarterly Operating Report is complete. The Quarterly Operating Report may be subject to future adjustment and reconciliation. The Quarterly Operating Report may also contain information for periods which are shorter or otherwise different from those required in the Company’s reports filed pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and such information might not be indicative of the Company’s financial condition or results of operations that are reflected in the Company’s financial statements or in its reports filed pursuant to the Exchange Act, including its Annual Report on Form 10-K for the year ended December 31, 2016, which the Company expects to file with the Securities and Exchange Commission within the prescribed time period (the “Form 10-K”). Furthermore, the information set forth in the Quarterly Operating Report should not be viewed as indicative of future results.

Investors are urged to consult the Form 10-K once it becomes available for the Company’s financial condition and results of operations for the year ended December 31, 2016, which includes the quarterly period covered by the Quarterly Operating Report.

A copy of the Quarterly Operating Report is attached as Exhibit 99.1 hereto and incorporated herein by reference. The Quarterly Operating Report annexed as Exhibit 99.1 hereto shall not be deemed an admission as to the materiality of any information disclosed therein.

 Cautionary Statement Regarding Forward-Looking Statements

The statements contained in this Current Report on Form 8-K that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 31E of the Exchange Act, including statements regarding the Company’s expectations, hopes, beliefs, intentions, or strategies regarding the future. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. All forward-looking statements included in this document are based on information available to the Company on the date hereof and the Company assumes no obligation to update any such forward-looking statement. Prospective investors should also consult the risks described from time to time in the Company’s Reports on Forms 10-K, 10-Q and 8-K.

Limitation on Incorporation by Reference

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 and in Exhibit 99.1 hereto is being furnished for informational purposes only and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, except as otherwise expressly stated in such filing. The filing of this Form 8-K shall not be deemed an admission as to the materiality of any information herein that is required to be disclosed solely by Regulation FD.

 Item 9.01. Financial Statements and Exhibits.     (d) Exhibits.     Exhibit Number   99.1          
        Description Quarterly Operating Report for the period between October 1, 2016 and December 31, 2016 filed with the United States Bankruptcy Court for the District of Delaware on January 31, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Nuo Therapeutics, Inc.
By:	/s/ David E. Jorden
	David E. Jorden
	Chief Executive Officer and Chief Financial Officer

Date: February 1, 2017

EX-99.1

Exhibit 99.1

OFFICE OF THE UNITED STATES TRUSTEE - REGION 3
POST-CONFIRMATION QUARTERLY SUMMARY REPORT

This Report is to be submitted for all bank accounts that are presently maintained by the post confirmation debtor.

Debtor's Name: Nuo Therapeutics, Inc.                                                             Bank: Capital One

Bankruptcy Number: 16-10192 (MFW)                                                            Account Number: All accounts

Date of Confirmation: May 5, 2016 (Effective Date)                                        Account Type: checking (operating), money market, CD

Reporting Period (month/year): October 1, 2016 – December 31, 2016

Beginning Cash Balance:	$	3,928,729
All receipts received by the debtor:
Cash Sales:	$	22,965
Collection of Accounts Receivable:	$	637,699
Proceeds from Litigation (settlement or otherwise):	$	0
Sale of Debtor's Assets:	$	100,000
Capital Infusion pursuant to the Plan:	$	0
Total of cash received:	$	760,664

Total of cash available:                                                                                                                                                                                                                                                                                                                                                                                                $    4,689,393

Less all disbursements or payments (including payments made under the confirmed plan) made by the Debtor:

Disbursements made under the plan, excluding the administrative

claims of bankruptcy professionals:                                                                                                                                                                                                                                                                                                                               $             4,172

Disbursements made pursuant to the administrative claims of

bankruptcy professionals:                                                                                                                                                                                                                                                                                                                                               $                   0

All other disbursements made in the ordinary course:                                                                                                                                                                                                                                                                                                                      $     2,011,708

Total Disbursements                                                                                                                                                                                                                                                                                                                                                                                                    $     2,015,880

Ending Cash Balance                                                                                                                                                                                                                                                                                                                                                                                                                     $     2,673,513

Pursuant to 28 U.S.C. Section 1746(2), I hereby declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge and belief.

01-31-2017                                                                             /s/ David E. Jorden 

Date                                                                                        David E. Jorden - CEO/CFO

Debtor: Nuo Therapeutics, Inc.
Case Number: 16-10192

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: December 31, 2016

QOR

CONSOLIDATED BALANCE SHEET (UNAUDITED) ¹

Line item	Current period
ASSETS
Current assets
Cash and cash equivalents and restricted cash		2,673,513
Accounts receivable		101,054
Other receivables		576,069
Inventory		75,358
Deposits		170,229
Prepaid expenses		230,071
Deferred costs, current portion		-
Total current assets		3,826,294
Property, plant and equipment
Aurix centrifuges		405,096
Computer and office equipment		17,436
Furniture and fixtures		31,452
Production equipment		34,899
Leasehold improvements		404,265
Software		257,619
Less: Accumulated depreciation		(664,651	)
Net property, plant and equipment		486,116
Other assets
Investment, Aldagen 1		-
Intangible assets, net of accumulated amortization		7,840,408
Goodwill		2,079,284
Other long-term assets		278,730
Total other assets		10,198,422
TOTAL ASSETS		14,510,832
LIABILITIES AND OWNERS' EQUITY
Liabilities not subject to compromise
Accounts payable		410,553
Accrued compensation and benefits		90,374
Accrued expenses		836,323
Accrued taxes		18,655
Customer deposits		-
Other long-term liabilities		123,434
Total liabilities not subject to compromise		1,479,339
Liabilities subject to compromise
Accounts payable		27,799
Accrued compensation and benefits		-
Accrued expenses		612
Accrued taxes		16,722
Customer deposits		70,737
Other long-term liabilities		-
Total liabilities subject to compromise		115,870
Shareholders' equity
Common stock		993
Preferred Stock		3
Additional paid-in capital		18,105,657
Retained earnings / (losses), post-emergence		(5,191,030	)
Total shareholders' equity		12,915,623
TOTAL LIABILITIES AND OWNERS' EQUITY		14,510,832

1. The accounting systems are not principally designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The numbers presented in this schedule are subject to change as additional information is made available. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited, subject to future adjustments and should not be considered as consistent with generally accepted accounting principles (GAAP). NOTE: The unaudited balance sheet reported for December 31, 2016, includes the accounts of Nuo Therapeutics, Inc. and its wholly-owned and controlled subsidiary Aldagen, Inc. ("Aldagen"). All significant inter-company accounts and transactions have been eliminated in consolidation.